Biocon starts clinical study to evaluate efficacy of Itolizumab

Biocon starts clinical study to evaluate efficacy of Itolizumab This is a phase two randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naive patients with moderate to severely active Ulcerative Colitis (UC), Biocon said in a statement.

from Moneycontrol Business News https://ift.tt/u36vK1c
Posted by: at
Tags:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Start-up Street: Social justice and the start-up ecosystem

Disparities in start-ups are a global phenomenon and affirmative action is needed to ensure an equal opportunities environment for aspiring...